Sacituzumab Govitecan TNBC Application Resubmitted to FDA

December 3, 2019 – Immunomedics has resubmitted its biologics license application (BLA) to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (TNBC) who have received ≥2 prior therapies for metastatic disease. “We appreciate the FDA’s guidance during the resubmission period and look forward to working closely with the agency during the BLA review,” Behzad Aghazadeh, executive chairman of Immunomedics … (leggi tutto)